Clinical Trial Update: Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating cannabinoid target engagement in adults with Obsessive-Compulsive Disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obsessive-compulsive Disorder

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Obsessive-Compulsive Disorder | Phase 1, Phase 2 | Status: WITHDRAWN